These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038 [TBL] [Abstract][Full Text] [Related]
3. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296 [TBL] [Abstract][Full Text] [Related]
4. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802 [TBL] [Abstract][Full Text] [Related]
5. 8-Aminoquinolines: future role as antiprotozoal drugs. Tekwani BL; Walker LA Curr Opin Infect Dis; 2006 Dec; 19(6):623-31. PubMed ID: 17075340 [TBL] [Abstract][Full Text] [Related]
6. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Loiseau PM; Cojean S; Schrével J Parasite; 2011 May; 18(2):115-9. PubMed ID: 21678786 [TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. Garnier T; Brown MB; Lawrence MJ; Croft SL J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550 [TBL] [Abstract][Full Text] [Related]
9. [Leishmaniasis--oral treatment with hexadecylphosphocholine]. Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039 [TBL] [Abstract][Full Text] [Related]
10. Quinolines as chemotherapeutic agents for leishmaniasis. Reynolds KA; Loughlin WA; Young DJ Mini Rev Med Chem; 2013 Apr; 13(5):730-43. PubMed ID: 23469781 [TBL] [Abstract][Full Text] [Related]
11. Leishmaniasis: in search of new chemotherapeutic agents. Kinnamon KE; Steck EA; Loizeaux PS; Chapman WL; Waits VB; Hanson WL Am J Vet Res; 1980 Mar; 41(3):405-7. PubMed ID: 7369615 [TBL] [Abstract][Full Text] [Related]
12. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences. Ali A Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830 [TBL] [Abstract][Full Text] [Related]
14. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. López-Martín C; Pérez-Victoria JM; Carvalho L; Castanys S; Gamarro F Antimicrob Agents Chemother; 2008 Nov; 52(11):4030-6. PubMed ID: 18794384 [TBL] [Abstract][Full Text] [Related]
15. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents. Cruz LJ; Luque-Ortega JR; Rivas L; Albericio F Mol Pharm; 2009; 6(3):813-24. PubMed ID: 19317431 [TBL] [Abstract][Full Text] [Related]